会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Electrolyte for driving electrolytic capacitor and electrolytic
capacitor using the same
    • 用于驱动电解电容器和电解电容器的电解液
    • US5776358A
    • 1998-07-07
    • US732372
    • 1997-05-02
    • Nario NiiboNaoko YoshidaYoshinori Takamuku
    • Nario NiiboNaoko YoshidaYoshinori Takamuku
    • H01G9/035H01G9/02H01G9/022
    • H01G9/022
    • The invention relates to an electrolyte for driving electrolytic capacitor and an electrolytic capacitor using the same, and by preparing by using a solvent mainly composed of organic compound, and dissolving one or more solutes selected from the group consisting of inorganic acids and organic acids, more specifically adding and dissolving at least one of copolymers of polyethylene glycol and polypropylene glycol shown in formulas (1) and (2), or both of the copolymers of polyethylene glycol and polypropylene glycol shown in formulas (1) and (2) simultaneously, the spark generation voltage and chemical conversion factor of formed oxidation film are enhanced, thereby improving the reliability of the electrolytic capacitor.HO--(C.sub.2 H.sub.4 O).sub.n --(C.sub.3 H.sub.6 O).sub.m--(C.sub.2 H.sub.4 O).sub.n --H (1) (n and m are arbitrary natural numbers.) HO--�(C.sub.2 H.sub.4 O).sub.n --(C.sub.3 H.sub.6 O).sub.m !.sub.i --H(2) (n, m, and 1 are arbitrary natural numbers.)
    • PCT No.PCT / JP96 / 00473 Sec。 371日期:1997年5月2日 102(e)日期1997年5月2日PCT提交1996年2月29日PCT公布。 第WO96 / 27201号公报 日期1996年9月6日本发明涉及一种用于驱动电解电容器的电解质和使用其的电解电容器,并且通过使用主要由有机化合物组成的溶剂制备,并溶解一种或多种选自无机酸的溶质 和有机酸,更具体地加入和溶解式(1)和(2)所示的聚乙二醇和聚丙二醇的共聚物中的至少一种,或式(1)和(2)所示的聚乙二醇和聚丙二醇的共聚物, 2)同时,提高了形成的氧化膜的火花发生电压和化学转化率,从而提高了电解电容器的可靠性。HO-(C2H4O)n-(C3H6O)m-(C2H4O)nH(1)(n和 )HO - [(C2H4O)n-(C3H6O)m] iH(2)(n,m和1是任意的自然数)
    • 3. 发明申请
    • Drugs containing galectin 9
    • 含有半乳凝素的药物9
    • US20060134119A1
    • 2006-06-22
    • US10543193
    • 2003-08-21
    • Mitsuomi HirashimaNozomu NishiAkira YamauchiNaoko YoshidaMasako Seki
    • Mitsuomi HirashimaNozomu NishiAkira YamauchiNaoko YoshidaMasako Seki
    • A61K48/00A61K38/17A61K39/395
    • A61K38/1709C07K16/18
    • Galectin 9 exerts various functions depending on its localizations. On the other hand, galectin 9 is expected as participating in various biological functions. Thus, it has been required to clarify the detailed biological activities of galectin 9 and develop galectin 9-related techniques including development of drugs. Human galectin 9 shows a cytotoxic activity and an apoptosis-inducing activity on tumor cells but shows neither cytotoxic activity nor apoptosis-inducing activity on normal cells. Therefore, it is possible to employ galectin 9 proteins, galectin 9 agonists, galectin 9 antagonists, anti-galectin 9 binding protein antibodies, anti-galectin 9 binding sugar chain antibodies, galectin 9-producing, releasing or inducing substances, etc. as antitumor, antiallergic, immunosuppressive agents, drugs for autoimmune diseases, anti-inflammatory agents and active ingredients for adrenocortical steroid hormone alternatives.
    • Galectin 9根据其定位具有各种功能。 另一方面,半乳凝素9预期参与各种生物学功能。 因此,需要阐明半乳凝素9的详细生物学活性,并开发包含药物开发的半乳凝素9相关技术。 人半乳凝素9显示对肿瘤细胞的细胞毒活性和细胞凋亡诱导活性,但对正常细胞无细胞毒性活性或细胞凋亡诱导活性。 因此,可以使用半乳凝素9蛋白,半乳凝素9激动剂,半乳凝素9拮抗剂,抗半乳凝素9结合蛋白抗体,抗半乳凝素9结合糖链抗体,半乳凝素-9产生,释放或诱导物质等作为抗肿瘤剂 ,抗过敏药,免疫抑制剂,自身免疫性疾病药物,抗炎药和肾上腺皮质激素替代物的活性成分。
    • 6. 发明申请
    • Galectin 9-inducing factors
    • 半乳凝素9诱导因子
    • US20070042941A1
    • 2007-02-22
    • US10554721
    • 2004-04-28
    • Mitsuomi HirashimaNozomu NishiAkira YamauchiNaoko YoshidaMasako Seki
    • Mitsuomi HirashimaNozomu NishiAkira YamauchiNaoko YoshidaMasako Seki
    • A61K38/17C07K14/47C07H21/04C12P21/06
    • A61K38/1709C07K14/4726
    • It has been disclosed that Galectin 9, which is a physiologically active substance acting as a lectin, is expressed in various cells and a correlationship is observed between the expression level of galectin 9 and the metastatic ability of tumors. Therefore, it is presumed that galectin 9 would relate to various physiological phenomena. Thus, a substance allowing the control of galectin 9 production and release is expected as exerting an activity of inducing antitumor and/or anti-inflammatory actions, etc. Therefore, it is required to reveal the same. It has been found that a factor inducing the production and release of galectin 9, “galectin 9-inducing factor”, is contained in a certain solubilized tumor cell membrane fraction. This factor can be obtained as a concanavalin A-adsorbed fraction and as a concentrated active fraction by fractionation with an ion exchange column packed with Resource Q®, a hydroxyapatite column, etc. Assay reagents, drugs, assays, etc. can be developed by using the galectin 9-inducing activity of this factor.
    • 已经公开了作为凝集素的生理活性物质的半乳凝素9在各种细胞中表达,并且在半乳凝素9的表达水平与肿瘤的转移能力之间观察到相关性。 因此,推测半乳凝素9与各种生理现象有关。 因此,预期能够控制半乳凝素9的产生和释放的物质具有诱导抗肿瘤和/或抗炎作用的活性等。因此,需要显示它。 已经发现,诱导半乳凝素9的产生和释放的因子“半乳凝素9诱导因子”被包含在某些溶解的肿瘤细胞膜级分中。 可以通过用填充有Resource Q(R),羟基磷灰石柱等的离子交换柱进行分级,作为伴刀豆素A吸附级分和作为浓缩的活性级分获得该因子。可以使用测定试剂,药物,测定等 通过使用该因子的半乳凝素9诱导活性开发。